Literature DB >> 1468430

Comparative in vitro activity of clarithromycin. Spanish Collaborative Group.

E Loza1, J Martínez Beltrán, F Baquero, A León, R Cantón, B Garijo.   

Abstract

The activity in vitro of clarithromycin, a new macrolide, was compared to that of various antibiotics in tests using 3,880 clinical isolates. Clarithromycin was two times more active than erythromycin against Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, streptococci of groups C, G and F, Brucella melitensis, Legionella pneumophila and Mycoplasma spp., 16 times more active against Ureaplasma urealyticum and 2 to 4 times less active against Campylobacter spp. In general, clarithromycin showed intrinsic activity 2 to 4 times higher than that of roxithromycin and 4 to 8 times higher than that of miocamycin. Cross-resistance was found between the macrolides. Clarithromycin was bactericidal against Streptococcus spp. and Haemophilus influenzae.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1468430     DOI： 10.1007/bf01960892

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  10 in total

1.  Comparative in vitro potencies of nine new macrolides.

Authors:  P B Fernandes; D J Hardy
Journal:  Drugs Exp Clin Res       Date:  1988

Review 2.  Erythromycin.

Authors:  D C Brittain
Journal:  Med Clin North Am       Date:  1987-11       Impact factor: 5.456

3.  Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli.

Authors:  V Lorian; L D Sabath
Journal:  Appl Microbiol       Date:  1970-11

4.  In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents.

Authors:  S Floyd-Reising; J A Hindler; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

5.  Comparative in vitro activity of A-56268 (TE-031), a new macrolide antibiotic.

Authors:  R L Hodinka; K Jack-Wait; P H Gilligan
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

6.  Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria.

Authors:  N X Chin; N M Neu; P Labthavikul; G Saha; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

7.  In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms.

Authors:  C A Benson; J Segreti; F E Beaudette; D W Hines; L J Goodman; R L Kaplan; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

8.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

9.  Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae.

Authors:  J H Jorgensen; L A Maher; A W Howell
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

10.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191
  10 in total
  8 in total

1.  Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.

Authors:  Hazem E Hassan; Ahmed A Othman; Natalie D Eddington; Lynn Duffy; Li Xiao; Ken B Waites; David A Kaufman; Karen D Fairchild; Michael L Terrin; Rose M Viscardi
Journal:  J Clin Pharmacol       Date:  2010-11-23       Impact factor: 3.126

Review 2.  Management of listeriosis.

Authors:  H Hof; T Nichterlein; M Kretschmar
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 3.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

4.  Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  V Berry; C E Thorburn; S J Knott; G Woodnutt
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 5.  Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  S M Holliday; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

6.  Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.

Authors:  J E Conte; J A Golden; S Duncan; E McKenna; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp.

Authors:  L A Collins; C B Wennersten; M J Ferraro; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

Review 8.  Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.